Fibrogen Stock Performance
| FGEN Stock | USD 1.07 0.07 6.14% |
On a scale of 0 to 100, FibroGen holds a performance score of 5. The firm shows a Beta (market volatility) of 5.05, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, FibroGen will likely underperform. Please check FibroGen's potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to make a quick decision on whether FibroGen's price patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in FibroGen are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, FibroGen displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Exercise or conversion by K Yu of 3750 shares of FibroGen subject to Rule 16b-3 | 02/23/2024 |
2 | FibroGen Q4 Earnings Snapshot | 02/26/2024 |
3 | Disposition of 23168 shares by Christine Chung of FibroGen at 1.87 subject to Rule 16b-3 | 03/06/2024 |
4 | FibroGen appoints new Chief Medical Officer | 03/11/2024 |
5 | Aquestive Up as Anaphylm Pivotal Study Meets Goals | 03/18/2024 |
6 | 3 Nightmare Nasdaq Stocks Not Worth Holding Another Day | 03/20/2024 |
7 | Disposition of 782 shares by Thane Wettig of FibroGen at 2.58 subject to Rule 16b-3 | 03/22/2024 |
8 | Stoke Therapeutics Up on Upbeat Dravet Syndrome Study Data | 03/27/2024 |
9 | FibroGen stock slips after data for prostate cancer drug | 04/03/2024 |
10 | eFFECTOR Therapeutics Plunges 82 percent as NSCLC Study Fails | 04/05/2024 |
11 | Eyenovia Down 18 percent on Disappointing Corporate Update | 04/09/2024 |
12 | Disposition of 422 shares by Juan Graham of FibroGen at 1.87 subject to Rule 16b-3 | 04/12/2024 |
13 | Acquisition by Juan Graham of 120000 shares of FibroGen subject to Rule 16b-3 | 04/15/2024 |
14 | Intra-Cellular Up as Depression Drug Meets Study Goals | 04/17/2024 |
15 | Bio-Path Rises on Upbeat Updates From Blood Cancer Study | 04/19/2024 |
| Begin Period Cash Flow | 155.7 M |
FibroGen |
FibroGen Relative Risk vs. Return Landscape
If you would invest 97.00 in FibroGen on January 24, 2024 and sell it today you would earn a total of 10.00 from holding FibroGen or generate 10.31% return on investment over 90 days. FibroGen is currently generating 0.9739% in daily expected returns and assumes 14.0196% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than FibroGen, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
FibroGen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for FibroGen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as FibroGen, and traders can use it to determine the average amount a FibroGen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0695
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | FGEN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 14.02 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.97 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average FibroGen is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of FibroGen by adding it to a well-diversified portfolio.
FibroGen Fundamentals Growth
FibroGen Stock prices reflect investors' perceptions of the future prospects and financial health of FibroGen, and FibroGen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on FibroGen Stock performance.
| Return On Equity | -10.16 | ||||
| Return On Asset | -0.36 | ||||
| Profit Margin | (1.92) % | ||||
| Operating Margin | (3.81) % | ||||
| Current Valuation | 89.44 M | ||||
| Shares Outstanding | 98.77 M | ||||
| Price To Earning | 97.67 X | ||||
| Price To Book | 53.83 X | ||||
| Price To Sales | 0.87 X | ||||
| Revenue | 147.75 M | ||||
| Gross Profit | (159.21 M) | ||||
| EBITDA | (259.28 M) | ||||
| Net Income | (284.23 M) | ||||
| Cash And Equivalents | 438.13 M | ||||
| Cash Per Share | 4.67 X | ||||
| Total Debt | 170.46 M | ||||
| Debt To Equity | 0.89 % | ||||
| Current Ratio | 2.17 X | ||||
| Book Value Per Share | (2.07) X | ||||
| Cash Flow From Operations | (315.02 M) | ||||
| Earnings Per Share | (2.92) X | ||||
| Market Capitalization | 112.6 M | ||||
| Total Asset | 423.53 M | ||||
| Retained Earnings | (1.84 B) | ||||
| Working Capital | 113.89 M | ||||
| Current Asset | 200.56 M | ||||
| Current Liabilities | 67.18 M | ||||
About FibroGen Performance
To evaluate FibroGen Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when FibroGen generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare FibroGen Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand FibroGen market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents FibroGen's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 804.92 | 1,162 | |
| Return On Tangible Assets | (0.67) | (0.64) | |
| Return On Capital Employed | (1.31) | (1.24) | |
| Return On Assets | (0.67) | (0.64) | |
| Return On Equity | 1.39 | 0.74 |
Things to note about FibroGen performance evaluation
Checking the ongoing alerts about FibroGen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for FibroGen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| FibroGen is way too risky over 90 days horizon | |
| FibroGen has some characteristics of a very speculative penny stock | |
| FibroGen appears to be risky and price may revert if volatility continues | |
| FibroGen has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 147.75 M. Net Loss for the year was (284.23 M) with loss before overhead, payroll, taxes, and interest of (159.21 M). | |
| FibroGen currently holds about 438.13 M in cash with (315.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| FibroGen has a poor financial position based on the latest SEC disclosures | |
| Roughly 71.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Bio-Path Rises on Upbeat Updates From Blood Cancer Study |
- Analyzing FibroGen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether FibroGen's stock is overvalued or undervalued compared to its peers.
- Examining FibroGen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating FibroGen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of FibroGen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of FibroGen's stock. These opinions can provide insight into FibroGen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.Note that the FibroGen information on this page should be used as a complementary analysis to other FibroGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for FibroGen Stock analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is FibroGen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (2.92) | Revenue Per Share 1.518 | Quarterly Revenue Growth (0.21) | Return On Assets (0.36) |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.